title: Vasopeptidase Inhibition: A New Approach to the Management of Cardiovascular Disease.
abstract: Vasopeptidase inhibitors, a new class of cardiovascular compounds, inhibit both neutral endopeptidase, an enzyme that helps in the breakdown of vasodilator substances, and ACE. Simultaneous inhibition of neutral endopeptidase and ACE enhances peptides with vasodilatory properties, such as atrial natriuretic peptide, brain natriuretic peptide, and C type natriuretic peptide, and inhibits the production of the vasoconstrictor angiotensin II. The properties of these natriuretic peptides and their function in the regulation of the cardiovascular system are reviewed. Clinical results with vasopeptidase inhibitors and other therapeutic modalities based on the natriuretic peptide system in the treatment of hypertension and heart failure are also reviewed. Omapatrilat, an agent that has been recently evaluated, is an effective agent in lowering diastolic and particularly systolic blood pressures in a broad range of populations and may have beneficial effects beyond blood pressure control. The mechanism of action of omapatrilat and clinical results with this compound are discussed. (c)2000 by Le Jacq Communications, Inc.
authors: Division of Clinical Pathophysiology, University Hospital, Lausanne Switzerland.
authors: Bernard
authors: B
authors: Waeber